SCHEMBL4940476

SCHEMBL4940476

CS(=O)(=O)c1ccc(-c2cccs2)c(C(=O)O)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.51
KDM4E B2RXH2 2/20 0.43
SCD O00767 1/20 0.43
GPR35 Q9HC97 2/20 0.42
ACLY P53396 1/20 0.41
PTPN1 P18031 1/20 0.41
PTGS2 P35354 2/20 0.41
EIF4E P06730 1/20 0.39
ALDH1A1 P00352 2/20 0.39
MAPK1 P28482 2/20 0.39
NPC1 O15118 2/20 0.39
TP53 P04637 2/20 0.39
RAB9A P51151 2/20 0.39
KMT2A Q03164 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MEN1 O00255 1/20 0.39
PKM P14618 1/20 0.39
S1PR4 O95977 1/20 0.39
HPGD P15428 1/20 0.39
S1PR1 P21453 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4938007 0.85 KMT2A (0.45) KDM4ESCDPTGS2ALDH1A1NPC1
SCHEMBL1823757 0.78 GPR35 (0.52) LMNAKDM4EGPR35PTPN1ALDH1A1
SCHEMBL22636953 0.78 SCD (0.45) LMNAKDM4ESCDPTGS2ALDH1A1
SCHEMBL9671860 0.77 ALDH1A1 (0.50) LMNAKDM4EGPR35ACLYPTPN1
SCHEMBL16256690 0.77 PTPN1 (0.56) KDM4EGPR35ACLYPTPN1EIF4E
SCHEMBL2482769 0.77 SRPK1 (0.51) KDM4EGPR35PTPN1KMT2AMEN1
SCHEMBL3875822 0.77 LMNA (0.58) LMNAPTGS2HSD17B10
Hydrochloric Acid SCHEMBL1825977 0.76 GPR35 (0.51) LMNAKDM4EGPR35PTPN1ALDH1A1
SCHEMBL12279980 0.76 GPR35 (0.51) LMNAKDM4EGPR35PTPN1ALDH1A1
SCHEMBL1308794 0.76 GPR35 (0.46) LMNAKDM4EGPR35PTPN1EIF4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255144-A1 Acylated Piperidines as Glycine Transporter Inhibitors GLAXO GROUP LIMITED 2008-10-16 US disclosed
US-20080255144-A1 Acylated Piperidines as Glycine Transporter Inhibitors GLAXO GROUP LIMITED 2008-10-16 US disclosed
US-20080255144-A1 Acylated Piperidines as Glycine Transporter Inhibitors GLAXO GROUP LIMITED 2008-10-16 US disclosed
EP-1858869-A1 ACYLATED PIPERIDINES AS GLYCINE TRANSPORTER INHIBITORS GLAXO GROUP LIMITED (GB) 2007-11-28 EP disclosed
WO-2006094842-A1 ACYLATED PIPERIDIHES AS GLYCINE TRANSPORTER INHIBITORS GLAXO GROUP LIMITED (GB) 2006-09-14 WO disclosed
WO-2006094842-A1 ACYLATED PIPERIDIHES AS GLYCINE TRANSPORTER INHIBITORS GLAXO GROUP LIMITED (GB) 2006-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255144-A1 Acylated Piperidines as Glycine Transporter Inhibitors SLC1A1, SLC6A7, SLC1A2 LMNA 4248/4885KDM4E 1931/4885SCD 2214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.